Form 8-K - Current report:
SEC Accession No. 0001104659-25-047856
Filing Date
2025-05-13
Accepted
2025-05-13 16:26:54
Documents
16
Period of Report
2025-05-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2514879d1_8k.htm   iXBRL 8-K 32976
2 EXHIBIT 16.1 tm2514879d1_ex16-1.htm EX-16.1 2214
3 EXHIBIT 99.1 tm2514879d1_ex99-1.htm EX-99.1 15189
4 GRAPHIC tm2514879d1_ex99-1img01.jpg GRAPHIC 3186
  Complete submission text file 0001104659-25-047856.txt   237117

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA tvrd-20250512.xsd EX-101.SCH 3044
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE tvrd-20250512_lab.xml EX-101.LAB 34239
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tvrd-20250512_pre.xml EX-101.PRE 22378
18 EXTRACTED XBRL INSTANCE DOCUMENT tm2514879d1_8k_htm.xml XML 3695
Mailing Address 3 SUGAR CREEK CTR. BLVD. STE 525 SUGAR LAND TX 77478
Business Address 3 SUGAR CREEK CTR. BLVD. STE 525 SUGAR LAND TX 77478 (713) 489-8654
Tvardi Therapeutics, Inc. (Filer) CIK: 0001346830 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36279 | Film No.: 25940579
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)